KBC Group NV Boosts Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

KBC Group NV raised its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 236,318 shares of the specialty pharmaceutical company’s stock after buying an additional 8,014 shares during the quarter. KBC Group NV owned about 0.39% of Jazz Pharmaceuticals worth $29,103,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in JAZZ. Millennium Management LLC raised its position in shares of Jazz Pharmaceuticals by 1,808.4% during the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock valued at $48,122,000 after buying an additional 427,246 shares in the last quarter. Algert Global LLC bought a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $637,000. Creative Planning raised its position in Jazz Pharmaceuticals by 21.7% during the second quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company’s stock valued at $408,000 after purchasing an additional 680 shares during the period. Sanctuary Advisors LLC bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $213,000. Finally, SG Americas Securities LLC purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $752,000. Institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Robert W. Baird increased their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. TD Cowen cut their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $177.00.

Jazz Pharmaceuticals Stock Down 0.7 %

NASDAQ:JAZZ opened at $123.53 on Wednesday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market cap of $7.47 billion, a PE ratio of 17.40, a price-to-earnings-growth ratio of 0.87 and a beta of 0.56. The company has a 50-day moving average of $122.64 and a 200 day moving average of $115.70. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now owns 428,976 shares of the company’s stock, valued at $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,253 shares of company stock valued at $1,001,434. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.